Abstract
Leptin has been shown to have a wide repertoire of peripheral effects, some of which are mediated through the central nervous system and others that are induced through a direct action on target tissues. There is now evidence showing that leptin exerts some of its metabolic effects acting directly on peripheral tissues. The role of leptin has expanded from a narrow position in obesity to effects on biological processes, such as diabetes, appetite, thermogenesis, the immune system and reproduction. Here in a first part, we review preclinical evidence for direct effects on specific tissues (neurons, liver and muscle) and metabolic pathways. In a second part we review clinical evidence for leptin effects. In particular we review the effects of recombinant human leptin in lean, obese, diabetic subjects and in patients with congenital leptin deficiency or lipoatrophic diabetes. Additionally, while clinic leptin has not shown dramatic effects in obese / diabetic subjects with measurable serum leptin, in states of leptin deficiency treatment with leptin has been shown to have profound effects on body weight and appetite and insulin resistance.
Keywords: Leptin, thermogenesis, lipoatrophic, neurons, insulin
Current Pharmaceutical Design
Title: Leptin: From Animals to Humans
Volume: 9 Issue: 10
Author(s): Murielle M. Veniant and Carl P. LeBel
Affiliation:
Keywords: Leptin, thermogenesis, lipoatrophic, neurons, insulin
Abstract: Leptin has been shown to have a wide repertoire of peripheral effects, some of which are mediated through the central nervous system and others that are induced through a direct action on target tissues. There is now evidence showing that leptin exerts some of its metabolic effects acting directly on peripheral tissues. The role of leptin has expanded from a narrow position in obesity to effects on biological processes, such as diabetes, appetite, thermogenesis, the immune system and reproduction. Here in a first part, we review preclinical evidence for direct effects on specific tissues (neurons, liver and muscle) and metabolic pathways. In a second part we review clinical evidence for leptin effects. In particular we review the effects of recombinant human leptin in lean, obese, diabetic subjects and in patients with congenital leptin deficiency or lipoatrophic diabetes. Additionally, while clinic leptin has not shown dramatic effects in obese / diabetic subjects with measurable serum leptin, in states of leptin deficiency treatment with leptin has been shown to have profound effects on body weight and appetite and insulin resistance.
Export Options
About this article
Cite this article as:
Veniant M. Murielle and LeBel P. Carl, Leptin: From Animals to Humans, Current Pharmaceutical Design 2003; 9 (10) . https://dx.doi.org/10.2174/1381612033455369
DOI https://dx.doi.org/10.2174/1381612033455369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Adipose-Derived Factors During Nutritional Transitions
Current Nutrition & Food Science Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design Insulin Resistance in the HIV-Infected Population: The Potential Role of Mitochondrial Dysfunction
Current Drug Targets - Infectious Disorders The Insulin-sensitizing Role of the Fat Derived Hormone Adiponectin
Current Pharmaceutical Design Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology HIV-Therapy Associated Lipodystrophy: Experimental and Clinical Evidence for the Pathogenesis and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Adipose Tissue as a Target of HIV-1 Antiretroviral Drugs. Potential Consequences on Metabolic Regulations
Current Pharmaceutical Design Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients
Current Pharmaceutical Design Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research Relationship Between Polymerase Gamma (POLG) Polymorphisms and Antiretroviral Therapy-Induced Lipodystrophy in HIV-1 Infected Patients: A Case-Control Study
Current HIV Research Relationship Between Inflammation, Insulin Resistance and Type 2 Diabetes: Cause or Effect?
Current Diabetes Reviews Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued)